CorNeat Vision’s core technology consists of a biocompatible non-degradable biomimetic material that imitates the micro-structure of the human extracellular matrix (ECM) which is the collagen mesh that provides the structural and biochemical support to surrounding cells. Unlike scaffolds and other collagen matrices which are used for tissue repair and engineering and provide a temporary infrastructure for cellular growth, CorNeat Vision’s material strength and its non-degradable nature offer new applications and use cases that can significantly improve the lives of millions.
CorNeat Vision’s material technology can be viewed as an “ant farm” for human fibroblasts, which are the cells that synthesize the extracellular matrix. Fibroblasts play a critical role in wound healing and are the most common cells of connective tissue. The mechanical properties of our material are optimized to stimulate fibroblast migration and colonization. In vivo studies demonstrated abundant presence of fibroblasts and collagen fibrils within our material a few weeks following its implantation with no adverse immune system response, indicating progressive tissue integration.
While originally developed for permanently anchoring synthetic implants with surrounding tissue, CorNeat Vision has gradually extended the use of its biomimetic platform technology to support additional use cases. Our technology is poised to impact implant design and enable new solutions in diversified fields of medicine.
Our advanced cell technology enables us to permanently attach and integrate synthetic material with live human tissue without rejection. These findings offer new and innovative medical solutions in ophthalmology and beyond.
Below you can see two histopathological images of the synthetic ECM following a few months inside the rabbit ocular tissue, specifically sub-conjunctively. The synthetic ECM is the central layer that is lighter in hue, stained with H&E (Hematoxylin and Eosin stain). Cell nuclei are evident throughout as darker, purple dots, no inflammatory (rejection) response or capsule formation is evident surrounding the device and in some areas capillaries are seen penetrating this matrix.
Figure 1: red arrowheads - cell nuclei; light pink - artificial ECM; dark pink - local tissue
Figure 2: red arrowhead indicates a possible capillary; blue arrowhead points to spindle shape cells typical of fibroblasts; purple fibres, indicative of collagen, are evident and dispersed throughout the image
Figure 2 is stained with Masson trichrome. Masson trichrome accentuates collagen, a central part of our native ECM, that appears here in purple. As evident from this image the matrix, composed of synthetic polymeric chains, is full of collagen fibers that were laid there by residing fibroblasts from local tissue. This finding fortifies our initial assumptions that local tissue will invade the matrix while remaining viable and active. The deposition of collagen actually “hides” the synthetic fibers from our own immune system and metabolism thus embedding them permanently within our body. Another finding that stands out in the Masson trichrome stained image (figure 2) is the evidence of capillaries within the matrix, yet another strong indicator of permanent integration.
On the intellectual property (IP) front, CorNeat Vision has made extensive progress over the past few years. In order to protect our innovations, we registered intellectual property for both ophthalmic and non-ophthalmic devices, leveraging CorNeat bio-integration platform technology.
As of this date, we have filed five patent applications in various jurisdictions.
Our flagship device, the CorNeat KPro (‘Keratoprosthesis and uses thereof’), was granted a patent in eleven jurisdictions which include Europe, USA, China, Canada, Russia, Japan and Israel and is still pending in a few other jurisdictions.
In addition, our animal trial and other R&D activities resulted in new intellectual property. Accordingly, except for the above patent, we have four additional patent applications that have been filed.
The company continues to invest in the intellectual property front, protecting its innovative ideas and increasing its assets.